SIAE MICROELETTRONICA to Extend the Microwave Network in the State of Bahia for COELBA, Neoenergia Group
COELBA, part of the Neoenergia group, is one of the first Power utility companies in Latin America offering a fully digital energy distribution system. In their effort to modernize and improve the quality of life in the state of Bahia, COELBA decided to invest in the upgrade and extension of its wireless communication backbone.
The existing heterogeneous network comprised of satellite links and low frequency wireless links operating at 900MHz and 1,5Ghz. With the need of connecting new sites and transport new services COELBA decided to build a homogeneous, modern and reliable infrastructure across Bahia.
SIAE MICROELETTRONICA technology was selected to implement the modern wireless infrastructure maximising reliability with protected configurations, performances with high capacity bandwidth and providing a single network management system.
“SIAE MICROELETTRONICA has developed a strong footprint in the Brazilian market, especially in the energy segment, also thanks to the capability of delivering full turnkey project together with strong partner like KOFRE”, says Raphael Macedo, sales leader for vertical markets in Brazil, adding “This project extension award is the confirmation we are serving our customers in the best way”.
“SIAE MICROELETTRONICA is a reliable supplier and a reference brand when speaking of wireless communication for data transport in Brazil, implementing the most innovative technology in its solutions”, says Flávio Silva, Chief Technology Officer of KOFRE.
“COELBA is making a major investment in the modernization of the radio telecommunications system and sought high availability radios and companies with a strong presence in Brazil, guaranteeing maintenance, support and ensuring that the investment made will have a return in the desired term” said Carlos Alberto De Souza Costa, Telecommunications Operation and Maintenance Manager in COELBA.
-About SIAE MICROELETTRONICA –
SIAE MICROELETTRONICA, founded in 1952, is a leader in wireless communication technology. Present in over 25 countries it offers to national and multinational operators advanced technological solutions for microwave and millimetre wave transport, services and design. In 2014 the group has founded SM OPTICS, a company driving innovation in fiber based communication, counting on a proven management and R&D team with 20+ years of experience in the optical domain as well as delivering comprehensive professional services." For more information: www.siaemic.com
Follow us on LinkedIN
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
LivaNova Enters into Binding Letter of Intent to Sell its Cardiac Rhythm Management Business Franchise to MicroPort Scientific Corporation for $190 Million20.11.2017 08:43 | Pressemelding
LivaNova PLC (NASDAQ:LIVN) (“LivaNova”) and MicroPort Scientific Corporation (HK:00853) (“MicroPort”) today announced that the companies have entered into a binding Letter of Intent (“LOI”) for the sale of LivaNova’s Cardiac Rhythm Management (“CRM”) Business Franchise to MicroPort for $190 million in cash. The CRM Business Franchise develops, manufactures and markets products for the diagnosis, treatment and management of heart rhythm disorders and heart failures. CRM products include high-voltage defibrillators, cardiac resynchronization therapy devices and low-voltage pacemakers. The CRM Business Franchise generated approximately $249 million in net sales in fiscal year 2016 and has approximately 900 employees with operations chiefly in Clamart, France; Saluggia, Italy; and Santo Domingo, Dominican Republic. MicroPort is a leading medical device company, focused on innova
Chugai's Bispecific Antibody Emicizumab Meets Primary Endpoint in Phase lll Study20.11.2017 08:29 | Pressemelding
Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that the primary endpoint has been met for the global phase lll HAVEN 3 (NCT02847637) study evaluating emicizumab (ACE910) subcutaneous injection, once a week and once every two weeks, in patients with hemophilia A (12 years of age or older) without inhibitors to factor Vlll. A statistically significant reduction in the number of bleeds was confirmed in patients treated with emicizumab prophylaxis compared to those receiving no prophylactic treatment. The study also met a secondary endpoint that once-weekly emicizumab prophylaxis was superior to factor VIII prophylaxis, as demonstrated by a statistically significant and clinically meaningful reduction in treated bleeds in an intra-patient comparison of patients receiving emicizumab prophylaxis compared to their prior factor VIII prophylaxis. The most common adverse events with em
Fiorano Launches PSD2 Solution for Banks for Seamless Regulatory Compliance20.11.2017 08:00 | Pressemelding
Fiorano Software, a proven global leader in Integration Middleware and API Management, today announced the launch of Fiorano PSD2, a platform solution enabling banks to comply with the European Union’s Revised Payment Service Directive (PSD2) regulations. Fiorano’s end-to-end PSD2 solution is built on the industry's leading banking Integration and API Management infrastructure serving as an onramp for future eDigital Banking initiatives. Banks across Europe need to be PSD2 compliant by January 2018. They are also facing severe competition from FinTechs to improve online payments, customer engagement experiences and making cross-border payments safer. “By building on PSD2 as a solution on top of a tightly integrated API Management and ESB platform, Fiorano masks complex technical details, dramatically simplifies the time and effort for compliance,” said Mr. Atul Saini, CEO of Fio
Synteract Thought Leaders to Speak & Exhibit at Partnerships in Clinical Trials Europe in Amsterdam20.11.2017 08:00 | Pressemelding
(Booth #17) – Thought leaders from Synteract, a full-service, international contract research organization (CRO), will exhibit and present at Partnerships in Clinical Trials Europe (PCT), November 28-29, Amsterdam, Netherlands. With awareness of the shifting CRO landscape and the complexity this represents to biopharma companies as they make critical outsourcing decisions, Synteract invites attendees to “Pause to rethink what matters most from your CRO.” Vice President, Global Medical and Regulatory Affairs at Synteract, Dr. Martine Dehlinger-Kremer, will speak on “The EU Clinical Trials Regulation: Are you prepared for its implementation?” at the event on Tuesday, November 28 at noon. She will address how evolving industry needs are driving momentum towards implementation of a new regulation governing clinical trials, the expected impact on sponsors and necessary steps toward p
Record Attendance at Japan Content Showcase 2017!20.11.2017 03:00 | Pressemelding
Japan Content Showcase 2017 was held October 23-26 at Ikebukuro Sunshine City and the Shibuya Excel Hotel Tokyu. A record 19,549 people participated in sales meetings, excluding the TIMM Showcase Live. Other new records this year were 371 exhibiting groups from 27 countries and regions and 1,549 buyers from 48 countries and regions. There was a significant increase in overseas buyers this year, the 1022 foreign registrations representing an increase of more than 10% over last year. The number of non-Japanese Asian buyers increased by 6%, North Americans by 13%, South Americans by 44%, and Europeans by 49%. The number of Middle Eastern buyers doubled, and there were more than five times the number of Russian buyers as last year. French buyers were up 70%, Italians 60%, British 75%, and Germans 50%. Business matching was a new service offered by the organizers this year. Meeti
Shell, bio-bean and Coffee-Drinkers Collaborate to Help Power London’s Buses20.11.2017 00:01 | Pressemelding
Shell and bio-bean announce that together they are helping to power some of London’s buses using a biofuel made partly from waste coffee grounds. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171119005060/en/ Shell and bio-bean announce that together they are helping to power some of London's buses using a biofuel made partly from waste coffee grounds (Photo: Business Wire) The B20 biofuel contains a 20% bio-component which contains part coffee oil. The biofuel is being added to the London bus fuel supply chain and will help to power some of the buses; without need for modification. Biofuel provides a cleaner, more sustainable energy solution for buses across London’s network by decreasing emissions1. “Our Coffee Logs have already become the fuel of choice for households looking for a
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom